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Introduction
After cesarean section, hysterectomy is the second most
frequently performed major surgical procedure for women of
reproductive age in the United States. Approximately 600,000
hysterectomies are performed annually in the United States,
and an estimated 20 million U.S. women have had a hyster-
ectomy (1,2).
The previous summary of hysterectomy surveillance in the
United States described trends during 1980–1993 (3).
Hysterectomy rates declined during 1980–1986 and increased
steadily during 1988–1993. However, during the latter
period, the rates of vaginal hysterectomy, concomitant bilat-
eral oophorectomy, and laparoscopically assisted vaginal hys-
terectomy (LAVH) increased (3). To monitor recent increasing
trends in the number of hysterectomies performed in the
United States, data from the 1994–1999 National Hospital
Discharge Survey (NHDS) were analyzed.
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Abstract
Problem/Condition: Hysterectomy is the second most frequently performed surgical procedure, after cesarean section,
for women of reproductive age in the United States. Approximately 600,000 hysterectomies are performed annually in
the United States, and approximately 20 million U.S. women have had a hysterectomy.
Reporting Period Covered: This report covers data from 1994 through 1999
Description of System: Estimates of the population of U.S. female, civilian residents were used to compute rates for
this study. Population denominators were obtained from the U.S. Bureau of the Census. The National Hospital Dis-
charge Survey (NHDS) was the data source for this report. NHDS is conducted by CDC’s National Center for Health
Statistics. NHDS is an annual, multistage probability sample of short-stay patients (those hospitalized <30 days) dis-
charged from nonfederal hospitals in the United States.
Results and Interpretation: From 1994 through 1999, an estimated 3,525,237 hysterectomies were performed among
U.S. women aged >15 years, and the overall hysterectomy rate for U.S. female, civilian residents was 5.5 per 1,000
women. Although statistically significant increases for hysterectomy rates were observed from 1994 (5.1/1,000) through
1998 (5.8/1,000), the increase was limited and the curve remained nearly flat.
Women aged 40–44 years had a significantly higher hysterectomy rate compared with any other age group. During the
study period, 52% of all hysterectomies were performed among women aged <44 years. In addition, hysterectomy rates
per 1,000 in women aged 45–54 years increased significantly, from 8.9 in 1994 to 10 in 1999. The overall hysterectomy
rate for women living in the South was 6.5 per 1,000, which was significantly higher than the rate among women who
lived in either the Northeast (4.3) or the West (4.8) but not significantly higher than the rate among women who lived
in the Midwest (5.4). Uterine leiomyoma, endometriosis, and uterine prolapse were the most frequent diagnoses for
women aged >15 years. The percentage of uterine leiomyoma as a primary diagnosis for hysterectomy increased 10.2%
for white women, 7.8% for black women, and 23% for women of other races. Among women who had a hysterectomy
during the study period, 55% also had a bilateral oophorectomy. The proportion of all vaginal hysterectomies with
concomitant laparoscopy (LAVH) increased significantly, from 13% in 1994 to 28% in 1999. During this same period,
the percentage of cases of LAVH with concomitant bilateral oophorectomy increased significantly, from 20.4% in 1994
to 42.5% in 1999.
Public Health Actions: Continued monitoring of hysterectomy trends will be necessary to evaluate differences in
hysterectomy rates by age, most commonly associated diagnoses, whether leiomyomata as a primary discharge diagno-
sis continues to increase, and whether the increase in LAVH that occurred during the previous decade continues.
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Methods
Study Population, NHDS Data,
and Sampling
The population studied comprised women aged >15 years
who had a hysterectomy during 1994–1999. The estimated
population of U.S. female, civilian residents was used to com-
pute rates for this study. The population sample was obtained
from the U.S. Bureau of the Census and included in a docu-
mentation package from NHDS (4). Data from the NHDS
conducted by CDC’s National Center for Health Statistics
were analyzed. NHDS is an annual, multistage probability
sample of short-stay patients (those hospitalized <30 days)
discharged from nonfederal hospitals in the United States.
NHDS uses a modified three-stage probability design. The
stages are 1) primary sampling units (PSUs), 2) hospitals within
PSUs, and 3) discharges within hospitals. The modification
was characterized by the selection with certainty of the largest
PSUs and hospitals (5).
Definition of Variables
Age
The study participants were grouped by ages 15–24,
25–29, 30–34, 35–39, 40–44, 45–54, and >55 years. This
strategy ensured stable estimates in each age group and
matched the age groups used in the previous report (3).
Race
Participants were also grouped by race into white, black, or
other category, on the basis of medical record abstraction. The
other category included Asians, Pacific Islanders, American
Indians, Alaskan Natives, and other races not already speci-
fied. Missing race information ranged from 17.1% in 1995
to 20.5% in 1997.
In this report, patients of unknown race were allocated pro-
portionate to the racial distribution of known cases. When
examining proportions, the point estimates based on propor-
tional allocation would not differ from those based only on
known race. However, if rates were calculated where the
numerators were based only on patients with known race,
rates would be understated in all cases.
Geographic Region
The geographic areas included in the study were based on
the U.S. Bureau of the Census definition of the four regions
of the United States: Northeast (Connecticut, Maine, Massa-
chusetts, New Hampshire, New Jersey, New York, Pennsylva-
nia, Rhode Island, and Vermont); Midwest (Illinois, Indiana,
Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska,
North Dakota, Ohio, South Dakota, and Wisconsin); South
(Alabama, Arkansas, Delaware, District of Columbia, Florida,
Georgia, Kentucky, Louisiana, Maryland, Mississippi, North
Carolina, Oklahoma, South Carolina, Tennessee, Texas,
Virginia, and West Virginia); and West (Alaska, Arizona, Cali-
fornia, Colorado, Hawaii, Idaho, Montana, Nevada, New
Mexico, Oregon, Utah, Washington, and Wyoming).
Medical Classification
Estimates of diagnoses and procedures in NHDS were
derived from the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM). Women with
codes 68.3–68.5 were classified as having undergone hyster-
ectomy. ICD-9-CM code 65.5 or 65.6 identified concomi-
tant bilateral oophorectomy; ICD-9-CM code 54.21 indicated
laparoscopy as a procedure before 1997; and the new ICD-9-CM
code 68.51 identified LAVH since 1997. NHDS also pro-
vides information regarding whether the surgical
approach was an abdominal or vaginal hysterectomy. Radical
hysterectomy, ICD-9-CM 68.6 or 68.7, and pelvic eviscera-
tion performed for advanced pelvic cancer treatment (ICD-
9-CM 68.8) were excluded.
Because NHDS includes seven diagnostic codes, the fol-
lowing algorithm was used to define the leading cause of hys-
terectomy: 1) cancer was assigned as the leading cause of
hysterectomy if reproductive tract cancer or debulked cancer
of the urinary or intestinal tract were listed as a diagnosis;
2) precancerous condition was assigned as the cause of hys-
terectomy if a precancerous condition was listed as a diagno-
sis (e.g., endometrial hyperplasia or carcinoma in situ of the
cervix); 3) uterine leiomyoma, endometriosis, or uterine pro-
lapse, whichever was listed first, was assigned as the primary
diagnosis if cancer or a precancerous condition was not listed;
and 4) “other” was assigned as the primary diagnosis for the
remaining recorded diagnoses (6,7).
Statistical Analysis
Rates per 1,000 women aged >15 years in the U.S. civilian
resident population were computed. SUDAAN software was
used to account for the complex survey design (8). Data were
weighted to produce national estimates. Because discharges
were reallocated in cases where race was not reported,
SUDAAN could not be used to compute standard errors
directly for race-specific estimates. Therefore, the relative stan-
dard error computed with SUDAAN for participants of
known race was applied to each reallocated total. Trends in
both discharge rates and proportions were computed by
using SUDAAN and SAS (8,9). The yearly estimates and corre-
sponding covariance matrices were computed with SUDAAN
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and then put into SAS’s PROC CATMOD, where weighted
least-squares estimation was used to test for trends over time.
Results
From 1994 through 1999, an estimated 3,525,237 hyster-
ectomies were performed in the United States for women aged
>15 years. The overall hysterectomy rate was 5.5 per 1,000
women per year (95% confidence interval [CI] = 5–5.9) dur-
ing the 6-year study period (Table 1). Although statistically
significant increases were observed in rates from 1994 through
1998 (p for trend = 0.04), the increase was limited, and the
overall curve during this period was nearly flat. Rates appeared
to decline in 1999 (Figure 1).
The overall estimated hysterectomy rate for blacks was 6.2
per 1,000 and 5.9 per 1,000 for other races. The hysterec-
tomy rate for whites was 5.3 per 1,000. Differences in overall
rates by race were not statistically significant (Table 2). How-
ever, differences in hysterectomy rates among black and white
women aged 35–39 and 40–44 years were statistically signifi-
cant (p<0.05).
TABLE 1. Estimated numbers and rates* of hysterectomies,
by year — United States, 1994–1999
Year    No. Rate SE†
1994     536,496 5.1 0.25
1995     572,866 5.4 0.25
1996     584,359 5.5 0.27
1997     592,298 5.5 0.28
1998     633,836 5.8 0.32
1999     605,382 5.5 0.29
Total 3,525,237 5.5 0.22
* Per 1,000 female, civilian residents aged >15 years.†Standard error.
Women aged 40–44 years had a significantly higher rate of
hysterectomy (11.7; 95% CI = 10.7–12.6) than did any other
age group. During the study period, 52% of all hysterecto-
mies were performed among women aged <44 years. Hyster-
ectomy rates among women aged 45–54 years increased
significantly, from 8.9 per 1,000 in 1994 to 10 per 1,000
in 1999 (p for trend = 0.009) (Figure 2). The highest
hysterectomy rate was 16.8 per 1,000 in black women aged
40–44 years. White women aged 40–44 years had a hysterec-
tomy rate of 10.8 per 1,000, and women of other races aged
40–44 years had a hysterectomy rate of 12.4 per 1,000 (Table 2).
The overall hysterectomy rate for women living in the South
was 6.5 per 1,000 (95% CI = 5.6–7.5), which was signifi-
cantly higher than the rate for women living in either the
Northeast (4.3; 95% CI = 3.7–5) or the West (4.8; 95% CI =
4.2–5.4), but not significantly higher than the rate among
women who lived in the Midwest (5.4; 95% CI = 4.6–6.1)
(Figure 3). The average age at which women in the South
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FIGURE 1. Hysterectomy rates* — United States, 1994–1999
* Per 1,000 female, civilian residents aged >15 years.
TABLE 2. Estimated rates* of hysterectomy, by age and race of women who obtained the procedure — United States, 1994–1999
Race
White Black Other† All races
Age (yrs) Rate SE§ No. Rate SE No. Rate SE No. Rate SE No.
15–24 0.3 0.05 22,846 ¶ ¶ ¶ ¶ ¶ ¶ 0.2 0.03 24,556
25–29 2.8 0.30 123,658 1.9 0.34 15,399 1.7 0.44 5,467** 2.6 0.20   144,524
30–34 5.4 0.46 276,421 5.4 0.50 47,741 3.5 0.90 11,722 5.3 0.33 335,884
35–39 8.3 0.62 459,502 12.5 1.06 111,971 7.8 1.20 25,679 8.9 0.48 597,152
40–44 10.8 0.74 569,735 16.8 1.36 135,755 12.4 1.51 38,087 11.7 0.49 743,577
45–54 9.6 0.55 812,734 11.2 0.82 128,229 12.9 1.59 57,514 9.9 0.40 998,476
>55 3.6 0.21 599,765 3.0 0.29 52,151 5.3 0.88 29,152 3.6 0.15 681,068
Total 5.3 0.32 2,864,661 6.2 0.37 492,743 5.9 0.67 167,834 5.5 0.22 3,525,237
* Per 1,000 female, civilian residents in each age and race category. Rates by race were adjusted by redistributing the number of women for whom race
was unknown according to the known distribution of race in the National Hospital Discharge Survey. Rates were calculated by applying population
weights to the sum of the number of hysterectomies obtained each year, and then dividing this value by the sum of the population estimates for each year.
Population estimates were obtained from the U.S. Department of Commerce, U.S. Bureau of the Census.† Includes Asian, Pacific Islander, American Indian, Alaskan Native, and other races.§ Standard error.¶ Fewer than 30 women in the sample; numbers were too small for meaningful analysis.
** Based on 30–59 women in the sample; number was unreliable.
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underwent a hysterectomy was 44.5 years (95% CI = 44–45),
which was significantly younger than the average age of women
living in all other regions (p<0.05). The highest average
age was 49.1 years (95% CI = 48.4–49.9) for women in the
Northeast.
Uterine leiomyoma, endometriosis, and uterine prolapse
were the most frequent diagnoses for women undergoing
hysterectomy and accounted for 73% of all hysterectomies
during 1994–1999. The percentage of hysterectomies with a
diagnosis of uterine leiomyoma was 68% among black women,
33% in white women, and 45% among women of other races
(Table 3). Women in the >55-year age group had higher num-
bers of diagnoses of hyperplasia, cancer, and uterine prolapse,
whereas women in the age groups from 30 through 54 years
had higher numbers of cases of leiomyomata and endometriosis
(Table 4). From 1994 through 1999, the percentage of cancer
FIGURE 2. Hysterectomy rates,* by age group — United States,
1994–1999
* Per 1,000 female, civilian residents in each age group.
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FIGURE 3. Hysterectomy rates,* by geographic region† —
United States, 1994–1999
* Per 1,000 female, civilian residents aged >15 years.† Regions are defined as follows: Northeast (Connecticut, Maine,
Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania,
Rhode Island, and Vermont); Midwest (Illinois, Indiana, Iowa, Kansas,
Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South
Dakota, and Wisconsin); South (Alabama, Arkansas, Delaware, District
of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi,
North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia,
and West Virginia); and West (Alaska, Arizona, California, Colorado,
Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington,
and Wyoming).
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as a primary diagnosis for hysterectomy significantly decreased
by 20% (p for trend = 0.01), and uterine leiomyoma increased
significantly by 11% (p for trend = 0.02) (Figure 4). The per-
centage of uterine leiomyoma as a primary diagnosis for hys-
terectomy increased 10.2% among white women (p for trend
= 0.20), 7.8% among black women (p for trend = 0.08), and
23% among women of other races (p for trend = 0.42).
TABLE 3. Estimated rates* of hysterectomy, by race of women who obtained the procedure and primary discharge diagnosis —
United States, 1994–1999
Race
White Black Other† All races
Diagnosis Rate SE§ No. Rate SE No. Rate SE No. Rate SE No.
Endometrial
hyperplasia 0.2 0.02 108,486 0.1 0.02 8,615 0.2 0.04 4,550¶ 0.2 0.01 121,651
Endometriosis 1.1 0.08 564,191 0.6 0.09 46,806 0.7 0.10 19,837 1.0 0.06 630,834
Uterine
leiomyoma 1.8 0.10 954,166 4.2 0.29 332,786 2.6 0.33 74,834 2.1 0.08 1,361,786
Uterine prolapse 1.0 0.08 547,933 0.3 0.04 19,792 0.9 0.15 25,894 0.9 0.05 593,619
Other 0.7 0.06 391,112 0.6 0.05 44,662 0.8 0.13 21,376 0.7 0.04 457,150
Total 5.3 0.32 2,868,666 6.2 0.36 489,165 5.9 0.67 167,406 5.5 0.22 3,525,237
* Per 1,000 female, civilian residents aged >15 years in each diagnosis and race category. Rates by race were adjusted by redistributing the number of
women for whom race was unknown according to the known distribution of race in the National Hospital Discharge Survey. Rates were calculated by
applying population weights to the sum of the number of hysterectomies obtained each year, and then dividing this value by the sum of the population
estimates for each year. Population estimates were obtained from the U.S. Department of Commerce, U.S. Bureau of the Census.† Includes Asian, Pacific Islander, American Indian, Alaskan Native, and other races.§ Standard error.¶ Based on 30–59 women in the sample; number was unreliable.
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Abdominal hysterectomies were performed more frequently
than vaginal hysterectomies for all races. Black women were
more likely to undergo abdominal hysterectomy than white
women; conversely, white women were more likely to
undergo vaginal hysterectomy than black women (Figure 5).
The higher prevalence of leiomyoma among black women
might contribute to the higher proportion of abdominal hys-
terectomies in this group.
Among women who had a hysterectomy during 1994–1999,
55% had a bilateral oophorectomy. Among women aged
FIGURE 4. Percentage change in primary diagnosis of
hysterectomies performed* — United States, 1994–1999
* Among female, civilian residents aged >15 years.† Include cervical dysplasia and menstrual disturbances.
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FIGURE 5. Percentage of hysterectomies performed,* by type
of surgical approach and race of women who obtained the
procedure — United States, 1994–1999
* Among female, civilian residents aged >15 years.
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TABLE 4. Estimated rates* of hysterectomy, by age group of women who obtained the procedure and primary discharge diagnosis
— United States, 1994–1999
Diagnosis
Cancer Endometrial hyperplasis Endometriosis
Age (yrs) Rate SE† No. Rate SE No. Rate SE No.
15–24 § § § § § § 0.1 0.02 7,485¶
25–29 0.2 0.04 13,193 § § § 0.8 0.10 46,178
30–34 0.3 0.05 20,318 0.1 0.02 3,533¶ 1.7 0.16 106,575¶
35–39 0.4 0.04 29,246 0.1 0.02 8,026 2.3 0.17 156,330
40–44 0.6 0.06 36,906 0.2 0.04 13,792 2.3 0.16 143,718
45–54 0.6 0.05 64,802 0.5 0.05 44,990 1.4 0.10 136,060
>55 1.0 0.05 192,596 0.3 0.02 49,990 0.2 0.02 34,488
Total 0.6 0.03 360,197 0.2 0.01 121,651 1.0 0.06 630,834
Diagnosis
Uterine leiomyoma Uterine prolapse Other** Total
Age (yrs) Rate SE No. Rate SE No. Rate SE No. Rate SE No.
15–24 § § § § § § 0.1 0.02 10,772 0.2 0.03 24,556
25–29 0.2 0.04 12,312 0.3 0.05 17,173 1.0 0.10 54,348 2.6 0.20 144,524
30–34 1.1 0.10 69,836 0.8 0.09 47,816 1.4 0.11 87,806 5.3 0.33 335,884
35–39 3.3 0.19 222,206 1.2 0.12 77,818 1.5 0.13 103,526 8.9 0.48 597,152
40–44 6.3 0.26 399,277 1.3 0.14 80,342 1.1 0.09 69,542 11.7 0.49 743,577
45–54 5.5 0.22 553,641 1.3 0.08 126,851 0.7 0.06 72,132 9.9 0.40 998,476
>55 0.6 0.04 103,805 1.3 0.08 241,165 0.3 0.02 59,024 3.6 0.15 681,068
Total 2.1 0.08 1,361,786 0.9 0.05 593,619 0.7 0.04 457,150   5.5 0.22 3,525,237
* Per 1,000 female, civilian residents in each age category and diagnosis category. Rates were calculated by applying population weights to the sum of the
number of hysterectomies obtained each year, and then dividing this value by the sum of the population estimates for each year. Population estimates
were obtained from the U.S. Department of Commerce, U.S. Bureau of the Census.† Standard error.§ Fewer than 30 women in the sample; numbers were too small for meaningful analysis.¶ Based on 30–59 women in the sample; number was unreliable.
** Includes cervical dysplasia and menstrual disturbances.
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15–44 years who underwent a hysterectomy, approximately
one third (40%) had a concomitant bilateral oophorectomy,
and these women can be considered to have undergone surgi-
cal menopause. The percentage of bilateral oophorectomy was
highest (75%) for women aged 45–54 years. The proportion
of hysterectomies with concomitant bilateral oophorectomies
tended to increase with increasing age (Figure 6). Women who
had a bilateral oophorectomy were 4.4 times as likely to have
an abdominal, rather than a vaginal hysterectomy. Seventy-
one percent of bilateral oophorectomies were performed on
women whose primary diagnoses were benign (e.g.,
leiomyoma, endometriosis, or uterine prolapse).
The trends for all hysterectomies performed vaginally and
the percentage of all vaginal hysterectomies with concomi-
tant bilateral oophorectomies remained stable during 1994–
1999 (Figure 7). However, the proportion of all vaginal hys-
terectomies with concomitant LAVH increased significantly,
from 13% in 1994 to 28% in 1999 (p for trend <0.0001).
Further analyses were performed to assess LAVH trends.
During the study, the number of vaginal hysterectomies with
concomitant bilateral oophorectomies remained stable
(Figure 8). However, the percentage of vaginal hysterectomies
with concomitant bilateral oophorectomies that were assisted
by laparoscopy increased significantly, from 20.4% in 1994
to 42.5% in 1999 (p for trend <0.0001).
Discussion
Study findings indicated a limited, yet significant increase
in the rate of hysterectomies during 1994–1998. From 1994
through 1999, one in every nine women aged 35–45 years
had a hysterectomy. Women aged 40–44 years had a signifi-
cantly higher rate of hysterectomies than all other age groups.
The most common primary diagnoses for a hysterectomy were
uterine leiomyoma, endometriosis, and uterine prolapse (3).
Approximately one half of the women who had a hysterec-
tomy also had a bilateral oophorectomy. Rates of vaginal hys-
terectomies remained stable, although the proportion of
women who had an LAVH increased significantly by >2-fold.
Furthermore, the proportion of vaginal hysterectomies with
concomitant oophorectomies performed that were assisted by
LAVH approximately doubled during 1994–1999.
The findings in this report confirm and extend those noted
in previous reports: rates of hysterectomy were higher among
black women than among white women. Although differences
in overall hysterectomy rates among black and white women
were not significant, differences in age-specific rates (35–39
years and 40–44 years) were significant (3,10–13). Rates of
FIGURE 8. Numbers of vaginal hysterectomies with bilateral
oophorectomies and percentage that are accompanied by
laparoscopy* — United States, 1994–1999
* Among female, civilian residents aged >15 years.
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FIGURE 7. Percentage of all hysterectomies performed* by
vaginal route, percentage of vaginal hysterectomies with
concomitant oophorectomy, and percentage of vagnial
hysterectomies with concomitant laparoscopy — United
States, 1994–1999
* Among female, civilian residents aged >15 years.
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FIGURE 6. Percentage of hysterectomies with bilateral
oophorectomy,* by age group — United States, 1994–1999
* Among female, civilian residents in each age group.
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hysterectomy were also higher among women aged 40–44 years
(3,10,12–15) and women living in the South (3,10,12–14,16).
The availability of obstetricians and gynecologists, the
number of hospital beds per capita, and the type of health-
care insurance available might vary by region; these factors
might influence regional variation (17,18).
Uterine leiomyoma, which is the most common uterine
tumor, was the most frequent diagnosis associated with
hysterectomy. In addition, the overall rate of hysterectomy
attributable to uterine leiomyoma during 1994–1999 (2.1 per
1,000) increased by 17% over the rate for the previous study
period (1988–1993: 1.8 per 1,000) (3). More widespread avail-
ability of ultrasound in obstetrician-gynecologist clinics might
have increased the diagnosis of uterine leiomyoma (19). Find-
ings in this report do not include data to help explain reasons
for observed racial differences in the occurrence of leiomyoma
or hysterectomy rates among women aged 30–44 years. How-
ever, family history has been associated with leiomyoma,
prompting an ongoing search for genetic and other potential
risk factors shared by women from the same families (20). In
contrast with leiomyomas, cancer as a primary diagnosis for
hysterectomy decreased by 21% during the study period. A
recent report demonstrates that the reduction
occurred primarily in cervical cancers as a primary diagnosis
for hysterectomy. Data in this report indicate that the reduc-
tion might be a consequence of increased detection of pre-
cancerous lesions by Papanicolaou smear programs (21) and
of changes in choice of treatment for early lesions (22,23).
Although trends for bilateral oophorectomy remained stable
during 1994–1999, the percentage of hysterectomy with con-
comitant bilateral oophorectomy more than doubled from
1965 (25%) to the time of this evaluation (55%) (15). More
than one half of hysterectomies were accompanied by bilat-
eral oophorectomies, the majority of which were performed
abdominally. An evaluation of the indications for oophorec-
tomies is beyond the scope of this report. When vaginal hys-
terectomies included concomitant bilateral oophorectomy,
increases in the use of laparoscopic assistance were observed.
These increases might indicate a preference by surgeons for
increased visibility of the ovaries when oophorectomy is per-
formed (24). Bilateral oophorectomy might have diverse
implications for women’s health (e.g., ovarian cancer preven-
tion, need for hormone replacement therapy).
According to the analysis in this report, LAVH approxi-
mately doubled from 1994 to 1999, although rates of vaginal
hysterectomy remained stable. Since 1989, when LAVH was
first introduced, to 1999, the percentage of all hysterectomies
that were LAVHs increased significantly from 1% to 28%.
LAVHs are controversial, partly because of cost concerns
(25,26), although LAVH-associated benefits might include
shorter hospital stays, less pain, more rapid recovery, and fewer
complications. These benefits are relevant, however, only when
LAVH replaces abdominal hysterectomy, rather than substi-
tuting for unassisted vaginal hysterectomy (2,27).
Limitations
Several limitations exist in the data presented in this report.
For example, the denominator included all U.S. women, rather
than only those women who had not previously undergone a
hysterectomy, resulting in an underestimate of the true rates
of hysterectomy among those at risk in the United States. This
limitation, however, should not affect the ability to detect
trends over time as long as rates remain stable. Another limi-
tation was the assumption that the racial distribution of dis-
charges where race was not reported is the same as for
discharges where race was reported. This assumption is tenu-
ous because a recent evaluation indicates that race data might
be more likely to be missing for white women (28). Further-
more, random assignment would attenuate any differences
by race. Therefore, the race-specific estimates presented in this
report should be interpreted with caution. In addition,
pathology reports were not available to help confirm indica-
tions for the performance of hysterectomy. Finally, data
regarding socioeconomic status and parity were not available.
In summary, the data demonstrate limited but significant
increases in hysterectomy rates from 1994 through 1998, fol-
lowed by a decrease in 1999. During the study period, sig-
nificant increases were observed in the occurrence of
leiomyomas as a primary diagnosis for hysterectomy, whereas
significant decreases occurred in the reporting of cancer as a
primary diagnosis. Continued monitoring of hysterectomy
trends will be necessary to evaluate differences in hysterec-
tomy rates by age, most commonly associated diagnoses,
whether leiomyomata as a primary discharge diagnosis con-
tinues to increase, and whether the increase in LAVH that
occurred during the previous decade will continue.
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Abstract
Problem/Condition: Malaria is caused by four species of intraerythrocytic protozoa of the genus Plasmodium (i.e.,
P. falciparum, P. vivax, P. ovale, or P. malariae). Malaria is transmitted by the bite of an infective female Anopheles sp.
mosquito. The majority of malaria infections in the United States occur among persons who have traveled to areas with
ongoing transmission. In the United States, cases can occur through exposure to infected blood products, by congenital
transmission, or locally through mosquitoborne transmission. Malaria surveillance is conducted to identify episodes of
local transmission and to guide prevention recommendations for travelers.
Period Covered: Cases with onset of illness during 2000.
Description of System: Malaria cases confirmed by blood smear are reported to local and state health departments by
health-care providers or laboratory staff. Case investigations are conducted by local and state health departments, and
reports are transmitted to CDC through the National Malaria Surveillance System (NMSS). Data from NMSS serve as
the basis for this report.
Results: CDC received reports of 1,402 cases of malaria with an onset of symptoms during 2000 among persons in the
United States or one of its territories. This number represents a decrease of 9.0% from the 1,540 cases reported for
1999. P. falciparum, P. vivax, P. malariae, and P. ovale were identified in 43.6%, 37.2%, 4.8%, and 2.3% of cases,
respectively. Nine patients (0.6% of total) were infected by >2 species. The infecting species was unreported or undeter-
mined in 161 (11.5%) cases. Compared with 1999, the number of reported malaria cases acquired in Africa decreased
by 13.1% (n = 783), and a decrease of 3.3% (n = 238) occurred in cases acquired in Asia. Cases from the Americas
decreased by 1.1% (n = 271) from 1999. Of 825 U.S. civilians who acquired malaria abroad, 190 (23.0%) reported
that they had followed a chemoprophylactic drug regimen recommended by CDC for the area to which they had
traveled. Four patients became infected in the United States, two through congenital transmission and two through
probable induced transmission. Six deaths were attributed to malaria, four caused by P. falciparum, one caused by
P. malariae, and one by P. ovale.
Interpretation: The 9.0% decrease in malaria cases in 2000, compared with 1999, resulted primarily from decreases in
cases acquired in Africa and Asia. This decrease could have resulted from local changes in disease transmission,
decreased travel to these regions, fluctuation in reporting to state and local health departments, or an increased use of
effective antimalarial chemoprophylaxis. In the majority of reported cases, U.S. civilians who acquired infection abroad
were not on an appropriate chemoprophylaxis regimen for the country in which they acquired malaria.
Public Health Actions: Additional information was obtained concerning the six fatal cases and the four infections
acquired in the United States. Persons traveling to a malarious area should take one of the recommended chemopro-
phylaxis regimens appropriate for the region of travel, and travelers should use personal protection measures to prevent
mosquito bites. Any person who has been to a malarious area and who subsequently develops a fever or influenza-like
symptoms should seek medical care immediately and report their travel history to the clinician; investigation should
include a blood-film test for malaria. Malaria infections can be fatal if not diagnosed and treated promptly. Recom-
mendations concerning malaria prevention can be obtained from CDC by calling the Malaria Hotline at 770-488-7788
or by accessing CDC’s Internet site at http://www.cdc.gov/travel.
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Introduction
Malaria is caused by infection with one or more of four
species of Plasmodium (i.e., P. falciparum, P. vivax, P. ovale,
and P. malariae) that can infect humans. The infection is trans-
mitted by the bite of an infective female Anopheles sp. mos-
quito. Malaria infection remains a devastating global problem,
with an estimated 300–500 million cases occurring annually
(1). Forty-one percent of the world’s population lives in areas
where malaria is transmitted (e.g., parts of Africa, Asia, the
Middle East, Central and South America, Hispaniola, and
Oceania) (1), and 700,000–2.7 million persons die of
malaria each year, 75% of them African children (2). In pre-
vious years, malaria was endemic throughout much of the
continental United States; an estimated 600,000 cases occurred
during 1914 (3). During the late 1940s, a combination of
improved socioeconomic conditions, water management,
vector-control efforts, and case management was successful
at interrupting malaria transmission in the United States. Since
then, malaria case surveillance has been maintained to detect
locally acquired cases that could indicate the reintroduction
of transmission and to monitor patterns of antimalarial drug
resistance that guide prevention recommendations for U.S.
travelers. Anopheline mosquitos remain seasonally present in
all states except Hawaii.
Through 2000, the majority of cases of malaria diagnosed in
the United States have been imported from regions of the world
where malaria transmission is known to occur, although con-
genital infections and infections resulting from exposure to blood
or blood products are reported in the United States also. In addi-
tion, a limited number of cases are reported that might have
been acquired through local mosquitoborne transmission (4).
State and local health departments and CDC investigate
malaria cases acquired in the United States, and CDC ana-
lyzes data from imported cases to detect acquisition trends.
This information is used to guide malaria prevention recom-
mendations for travelers abroad. For example, an increase in
P. falciparum malaria among U.S. travelers to Africa, an area
with increasing chloroquine resistance, prompted CDC to
change the recommended chemoprophylaxis regimen from
chloroquine to mefloquine in 1990 (5).
The signs and symptoms of malaria illness are varied, but
the majority of patients experience fever. Other common
symptoms include headache, back pain, chills, increased sweat-
ing, myalgia, nausea, vomiting, diarrhea, and cough. The
diagnosis of malaria should be considered for persons who
experience these symptoms and who have traveled to an area
with known malaria transmission. Malaria should also be con-
sidered in the differential diagnoses of persons who experi-
ence fevers of unknown origin, regardless of their travel history.
Untreated P. falciparum infections can rapidly progress to coma,
renal failure, pulmonary edema, and death. Asymptomatic para-
sitemia can occur among persons who have been long-term
residents of malarious areas. This report summarizes malaria
cases reported to CDC with onset of symptoms in 2000.
Methods
Data Sources
Malaria case data are reported to the National Malaria Sur-
veillance System (NMSS) and the National Notifiable Dis-
eases Surveillance System (NNDSS) (6). Although both
systems rely on passive reporting, the numbers of reported
cases might differ between the two systems because of differ-
ences in collection and transmission of data. A major differ-
ence in the data collected in these two systems is that NMSS
receives more detailed clinical and epidemiologic data regard-
ing each case (e.g., information concerning the area to which
the infected person has traveled). This report presents only
data regarding cases reported to NMSS.
Cases of blood-film–confirmed malaria among civilians and
military personnel are identified by health-care providers or
laboratories. Each slide-confirmed case is reported to local or
state health departments and to CDC on a uniform case
report form that contains clinical, laboratory, and epidemio-
logic information. CDC staff review all report forms when
received and request additional information, if necessary (e.g.,
when no recent travel to a malarious country is reported).
Reports of other cases are telephoned directly by health-care
providers to CDC, usually when assistance with diagnosis or
treatment is requested. All cases that have been acquired in
the United States are investigated, including all induced and
congenital cases and possible introduced or cryptic cases.
Information derived from uniform case report forms is
entered into a database and analyzed annually.
Definitions
The following definitions are used in this report:
• Laboratory criteria for diagnosis: Demonstration of
malaria parasites in blood films.
• Confirmed case: Symptomatic or asymptomatic infec-
tion that occurs in a person in the United States who has
microscopically confirmed malaria parasitemia, regard-
less of whether the person had previous episodes of
malaria while in other countries. A subsequent episode
of malaria is counted as an additional case if the identi-
fied Plasmodium sp. differs from the initially identified
species. A subsequent episode of malaria occurring in a
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person while in the United States could indicate a relaps-
ing infection or treatment failure resulting from drug
resistance if the identified Plasmodium sp. is the same spe-
cies identified previously.
This report also uses terminology derived from the recom-
mendations of the World Health Organization (7). Defini-
tions of the following terms are included for reference:
• Autochthonous malaria:
Indigenous. Mosquitoborne transmission of malaria in
a geographic area where malaria occurs regularly.
Introduced. Mosquitoborne transmission of malaria from
an imported case in an area where malaria does not occur
regularly.
• Imported malaria: Malaria acquired outside a specific
area. In this report, imported cases are those acquired
outside the United States and its territories (Puerto Rico,
Guam, and the U.S. Virgin Islands).
• Induced malaria: Malaria acquired through artificial means
(e.g., blood transfusion or using shared common syringes).
• Relapsing malaria: Renewed manifestations (i.e., clini-
cal symptoms or parasitemia) of malarial infection that is
separated from previous manifestations of the same
infection by an interval greater than the usual periodicity
of the paroxysms.
• Cryptic malaria: An isolated malaria case that cannot be
linked epidemiologically to secondary cases.
Microscopic Diagnosis of Malaria
The early diagnosis of malaria requires that physicians con-
sider malaria in the differential diagnosis of every patient who
is experiencing fever; the evaluation of such a patient should
include taking a comprehensive travel history. If malaria is
suspected, a Giemsa-stained smear of the patient’s peripheral
blood should be examined for parasites. Thick and thin blood
films must be prepared correctly because diagnostic accuracy
depends on blood-film quality and examination by experi-
enced laboratory personnel* (see Appendix for procedures for
accurately diagnosing malaria).
Results
General Surveillance
During 2000, CDC received 1,402 malaria case reports
occurring among persons in the United States and its territories,
representing a 9.0% decrease from the 1,540 cases reported
for 1999 (8). This incidence is the third highest number of
reported cases since 1980 and represents the second highest
number of U.S. civilian cases reported in the past 30 years
(Table 1). In 2000, a total of 827 cases occurred among U.S.
civilians, compared with 833 cases reported for 1999, and
the number of cases among foreign civilians also decreased
from 381 cases to 354 (Figure 1). Cases among U.S. military
personnel decreased from 55 to 46 in 2000. In 175 cases, infor-
mation was insufficient to determine civilian or military status.
* To obtain confirmation diagnosis of blood films from questionable cases
and to obtain appropriate treatment recommendations, contact either your
state or local health department or CDC’s National Center for Infectious
Diseases, Division of Parasitic Diseases, Malaria Epidemiology Branch at
770-488-7788.
TABLE 1. Number of malaria cases* among U.S. and foreign
civilians and U.S. military personnel — United States, 1971–
2000
U.S. military U.S. Foreign Status
Year personnel civilians civilians not recorded Total
1971 2,975 79 69 57 3,180
1972 454 106 54 0 614
1973 41 103 78 0 222
1974 21 158 144 0 323
1975 17 199 232 0 448
1976 5 178 227 5 415
1977 11 233 237 0 481
1978 31 270 315 0 616
1979 11 229 634 3 877
1980 26 303 1,534 1 1,864
1981 21 273 809 0 1,103
1982 8 348 574 0 930
1983 10 325 468 0 803
1984 24 360 632 0 1,016
1985 31 446 568 0 1,045
1986 35 410 646 0 1,091
1987 23 421 488 0 932
1988 33 550 440 0 1,023
1989 35 591 476 0 1,102
1990 36 558 504 0 1,098
1991 22 585 439 0 1,046
1992 29 394 481 6 910
1993 278 519 453 25 1,275
1994 38 524 370 82 1,014
1995 12 599 461 95 1,167
1996 32 618 636 106 1,392
1997 28 698 592 226 1,544
1998 22 636 361 208 1,227
1999 55 833 381 271 1,540
2000 46 827 354 175 1,402
* A case was defined as symptomatic or asymptomatic illness that occurs
in the United States in a person who has microscopy-confirmed malaria
parasitemia, regardless of whether the person had previous attacks of
malaria while in other countries. A subsequent attack of malaria occurring
in a person is counted as an additional case if the demonstrated
Plasmodium species differs from the initially identified species. A
subsequent attack of malaria occurring in a person while in the United
States could indicate a relapsing infection or treatment failure resulting
from drug resistance if the demonstrated Plasmodium species is the
same species identified previously.
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Plasmodium Species
The infecting species of Plasmodium was identified in 1,241
(88.5%) of the cases reported in 2000. P. falciparum and
P. vivax were identified in blood smears from 43.6% and
37.2% of infected persons, respectively (Table 2). The 611
P. falciparum cases reported for 2000 represented a 13.7%
decrease from the 708 cases in 1999, whereas the number of
P. vivax infections increased by 10.6% (from 472 in 1999 to
522 in 2000). Among 1,181 cases in which both the region
of acquisition and the infecting species were known, 75.6%
of infections acquired in Africa were attributed to P. falciparum;
13.2% were attributed to P. vivax. The converse was true of
infections acquired in the Americas and Asia: 86.5% and
85.9% were attributed to P. vivax, and only 7.3% and 8.3%
were attributed to P. falciparum, respectively.
Region of Acquisition and Diagnosis
Approximately 99% (n = 1,398) of reported cases were
imported. Of 1,330 imported cases in which the region of
acquisition was known, the majority (58.9%; n = 783) were
acquired in Africa; 20.1% (n = 271) and 17.9% (n = 238)
were acquired in the Americas and Asia, respectively (Table 3).
The highest concentration of cases acquired in Africa came
from countries in West Africa (66.7%; n = 522), whereas the
majority of cases acquired in Asia came from the Indian sub-
continent (67.2%; n = 160). The other regions where
imported cases of malaria were acquired were Central America
and the Caribbean (15.0%; n = 200), South America (4.3%;
n = 57), and Oceania (1.7%; n = 22). Information regarding
region of acquisition was missing for 68 (4.9%) of the
imported cases. The number of reported malaria cases acquired
in Africa decreased by 13.1% (n = 783), compared with 1999.
The same number of cases acquired in the Americas (n = 271)
were reported for 2000 as compared with 1999. Cases from
Asia decreased by 3.3% (n = 238), compared with 1999.
In the United States, the five health departments reporting
the highest number of malaria cases were New York City
(n = 220), California (n = 194), New York State (n = 77),
Texas (n = 70), and Illinois (n = 67) (Figure 2). All of these
health departments reported a decrease in cases compared with
1999. This overall decrease in reported number of cases might
reflect a decreased rate of international travel, a reduced risk
for malaria among travelers, poorer access to health care, or
fluctuation in surveillance by state and local health departments.
Interval Between Arrival and Illness
The interval between date of arrival in the United States
and onset of illness and the infecting Plasmodium species were
known for 623 (44.6%) of the imported cases of malaria
(Table 4). Symptoms began before arrival in the United States
for 63 (10.1%) persons, whereas symptoms began after
arrival in the United States for 560 (89.9%) of these patients.
Clinical malaria developed within 1 month after arrival in
313 (80.9%) of the 387 P. falciparum cases and in 75 (38.9%)
of the 193 P. vivax cases (Table 4). Only 5 (0.8%) of the 560
persons became ill >1 year after returning to the United States.
TABLE 2. Number of malaria cases, by Plasmodium
species — United States, 1999 and 2000
Plasmodium 1999 2000
Species No. (%) No. (%)
P. falciparum 708 (46.0) 611 (43.6)
P. vivax 472 (30.7) 522 (37.2)
P. malariae 70 (4.6) 67 (4.8)
P. ovale 55 (3.6) 32 (2.3)
Mixed 12 (0.8) 9 (0.6)
Undetermined 223 (14.5) 161 (11.5)
Total 1,540 (100.0) 1,402 (100.0)
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FIGURE 1. Number of malaria cases among U.S. and foreign
civilians — United States,* 1971–2000†
* Includes Puerto Rico, Guam, and the U.S. Virgin Islands.† The substantial increase in the number of cases reported for 1980 primarily
reflects cases diagnosed among immigrants from Southeast Asia.
*Excludes New York City.
FIGURE 2. Number of malaria cases, by state in which the
disease was diagnosed — United States, 2000
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TABLE 3. Imported malaria cases, by country of acquisition and Plasmodium species — United States, 2000
Country Plasmodium species
of acquisition P. falciparum P. vivax P. malariae P. ovale Unknown Mixed Total
Africa 528 92 40 31 85 7 783
Algeria 0 1 0 0 0 0 1
Angola 3 2 1 0 1 1 8
Benin 2 3 0 0 0 0 5
Botswana 0 0 0 0 1 0 1
Burkina Faso 3 1 0 0 0 0 4
Burundi 0 1 0 0 0 0 1
Cameroon 17 2 2 2 5 0 28
Central African Republic 1 0 0 0 0 0 1
Chad 1 0 0 0 0 0 1
Congo 3 4 1 1 1 0 10
Cote d’Ivoire 32 2 2 3 3 1 43
Democratic Republic of the Congo (Zaire) 2 0 0 0 0 0 2
Eritrea 0 1 0 0 1 0 2
Ethiopia 0 6 2 1 0 0 9
Gabon 2 2 0 1 2 0 7
Gambia 18 3 0 1 1 0 23
Ghana 97 10 4 3 16 0 130
Guinea 11 4 0 0 1 0 16
Kenya 19 8 4 5 3 0 39
Liberia 19 1 3 0 10 1 34
Libya 1 0 0 0 0 0 1
Madagascar 4 3 0 0 0 0 7
Malawi 2 0 0 1 0 0 3
Mali 16 1 1 0 0 0 18
Mauritania 1 3 1 0 0 1 6
Mozambique 4 2 0 0 1 0 7
Niger 2 1 0 0 0 0 3
Nigeria 143 7 5 5 17 0 177
Rwanda 0 1 1 0 0 1 3
Senegal 25 1 2 1 1 0 30
Sierra Leone 9 0 0 0 0 0 9
Somali Republic 2 0 0 0 0 0 2
South Africa 3 1 0 0 1 0 5
Sudan 5 1 2 0 0 0 8
Tanzania 11 3 1 0 4 0 19
Togo 2 2 0 2 0 0 6
Uganda 18 2 2 1 3 0 26
Zambia 6 1 0 0 0 0 7
Zimbabwe 3 1 0 0 3 0 7
West Africa, unspecified* 16 2 1 2 2 1 24
Central Africa, unspecified* 1 0 0 0 0 0 1
East Africa, unspecified* 0 0 0 0 1 0 1
Africa, unspecified 24 9 5 2 7 1 48
Asia 17 176 11 1 33 0 238
Afghanistan 0 2 0 0 0 0 2
Bangladesh 1 0 0 0 1 0 2
Bhutan 0 1 0 0 0 0 1
Burma (Myanmar) 0 1 0 0 0 0 1
Cambodia 0 1 0 0 0 0 1
China 0 1 0 0 1 0 2
India 6 104 8 1 20 0 139
Indonesia 3 15 1 0 4 0 23
Iran 0 2 0 0 0 0 2
Korea (South) 0 21 1 0 2 0 24
Laos 1 0 0 0 0 0 1
Pakistan 0 11 1 0 3 0 15
Philippines 0 6 0 0 0 0 6
Saudi Arabia 1 0 0 0 0 0 1
Sri Lanka 0 1 0 0 0 0 1
Thailand 2 5 0 0 1 0 8
Turkey 1 0 0 0 0 0 1
Yemen 1 2 0 0 0 0 3
Middle East 1 0 0 0 0 0 1
Southeast Asia, unspecified 0 3 0 0 1 0 4
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Imported Malaria Cases
Imported Malaria Among U.S. Military
Personnel
In 2000, a total of 46 cases of imported malaria were
reported among U.S. military personnel. Of the 45 cases for
whom information regarding chemoprophylaxis use was avail-
able, seven patients were not using any prophylaxis.
Imported Malaria Among Civilians
A total of 1,179 imported malaria cases were reported among
civilians. Of these, 825 (70.0%) cases occurred among U.S.
residents, and 354 (30.0%) cases occurred among residents
of other countries (Table 5). Of the 825 imported malaria
cases among U.S. civilians, 555 (67.3%) had been acquired
in Africa, an increase of 1.1% from cases reported in 1999.
Asia accounted for 106 (12.8%) cases of imported malaria
among U.S. civilians, whereas travel to the Central American
and Caribbean regions accounted for an additional 90 (10.9%)
cases. Of the 354 imported cases among foreign civilians, the
majority of cases were acquired in either Africa (n = 150;
42.4%) or Asia (n = 90; 25.4%).
TABLE 4. Number of imported malaria cases, by interval between date of arrival in the United States and onset of illness and
Plasmodium species* — United States, 2000
P. falciparum P. vivax P. malariae P. ovale Mixed Total
Interval (days) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
<0† 46 (11.9) 15 (7.8) 1 (3.8) 1 (8.3) 0 (0) 63 (10.1)
0–29 313 (80.9) 75 (38.9) 8 (30.8) 3 (25.0) 3 (60.0) 402 (64.5)
30–89 19 (4.9) 45 (23.3) 7 (26.9) 1 (8.3) 2 (40.0) 74 (11.9)
90–179 7 (1.8) 28 (14.5) 7 (26.9) 4 (33.3) 0 (0) 46 (7.4)
180–364 1 (0.3) 28 (14.5) 2 (7.7) 2 (16.7) 0 (0) 33 (5.3)
>365 1 (0.3) 2 (1.0) 1 (3.8) 1 (8.3) 0 (0) 5 (0.8)
Total 387 (100.0) 193 (100.0) 26 (100.0) 12 (100.0) 5 (100.0) 623 (100.0)
* Persons for whom Plasmodium species, date of arrival in the United States, or date of onset of illness is unknown are not included.† Persons in these cases had onset of illness before arriving in the United States.
TABLE 3. (Continued) Imported malaria cases, by country of acquisition and Plasmodium species — United States, 2000
Country Plasmodium species
of acquisition P. falciparum P. vivax P. malariae P. ovale Unknown Mixed Total
Central America and the Caribbean 22 147 8 0 22 1 200
Belize 1 2 0 0 0 0 3
Costa Rica 0 3 0 0 1 0 4
El Salvador 2 27 1 0 5 1 35
Guadeloupe 1 0 0 0 0 0 1
Guatemala 0 26 1 0 1 0 28
Haiti 14 0 0 0 1 0 15
Honduras 3 73 6 0 12 1 95
Nicaragua 1 12 0 0 0 0 13
Central America, unspecified 0 4 0 0 2 0 6
North America 2 24 1 0 3 0 30
Mexico 2 24 1 0 3 0 30
South America 9 41 3 0 4 0 57
Bolivia 0 1 0 0 0 0 1
Brazil 1 9 1 0 1 0 12
Columbia 1 2 0 0 0 0 3
Ecuador 4 24 1 0 1 0 30
Guyana 3 3 1 0 1 0 8
Peru 0 1 0 0 1 0 2
Surinam 0 1 0 0 0 0 1
Oceania 2 17 1 0 2 0 22
Papua New Guinea 2 14 1 0 2 0 19
Solomon Islands 0 3 0 0 0 0 3
Europe/Newly Independent States 0 0 0 0 0 0 0
Unknown 29 24 2 0 12 1 68
Total 609 521 66 32 161 9 1,398
* East, West, and Central Africa: Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde Islands, Central African Republic, Chad, Comoros,
Congo, Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-
Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Niger, Nigeria, Réunion, Rwanda, São Tomé and Príncipe,
Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Togo, Uganda, Tanzania, Zambia, and Zimbabwe.
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Antimalarial Chemoprophylaxis Use
Chemoprophylaxis Use Among U.S. Civilians
Information concerning chemoprophylaxis use and travel
area was known for 758 (91.9%) of the 825 U.S. civilians
who had imported malaria. Of these 758 persons, 452 (59.6%)
had not taken any chemoprophylaxis, and 94 (12.4%) had
not taken a CDC-recommended drug for the area visited (9).
Only 190 (25.1%) U.S. civilians had taken a CDC-
recommended medication (9). Data for the specific drug taken
were missing for the remaining 22 (2.9%) travelers. A total of
128 (67.4%) patients on CDC-recommended prophylaxis had
taken mefloquine weekly; 22 (11.6%) had taken doxycycline
daily; and 21 (11.1%) who had traveled only in areas where
chloroquine-resistant malaria has not been documented, had
taken chloroquine weekly. Nineteen patients (10.0%) had
taken combinations of drugs that included >1 CDC-
recommended drugs for the travel region. Of the 94 patients
taking a nonrecommended drug, 54 (57.4%) reported taking
chloroquine either alone or in combination with another
ineffective drug during travel to an area where chloroquine
resistance has been documented.
Malaria Infection After Recommended
Prophylaxis Use
A total of 236 patients (i.e., 190 U.S. civilians, 32 persons
in the U.S. military, 6 foreign civilians, and 8 persons whose
information regarding their status was missing) experienced
malaria after taking a recommended antimalarial drug for
chemoprophylaxis. Information regarding infecting species was
available for 209 (88.6%) patients taking a recommended
antimalarial drug; the infecting species was undetermined for
the remaining 27.
Cases of P. vivax or P. ovale After Recommended Pro-
phylaxis Use. Of the 236 patients who experienced malaria
after recommended chemoprophylaxis use, 121 cases (51.3%)
were caused by P. vivax and 10 (4.2%) by P. ovale. Notes on
the malaria case surveillance reports indicated that 25 (19.1%)
of these 131 patients were noncompliant with antimalarial
prophylaxis.
A total of 39 (29.8%) cases of P. vivax or P. ovale occurred
>45 days after arrival in the United States. These cases were
consistent with relapsing infections and, thus, do not indi-
cate prophylaxis failures. Information was insufficient, because
of missing data regarding symptom onset or return date, to
assess whether 77 cases were relapsing infections. Fifteen cases,
all caused by P. vivax, occurred <45 days after the patient
returned (n = 12) or before return (n = 3) to the United States.
Of these 15 patients, five were known to be noncompliant
with their antimalarial chemoprophylaxis. Region of acquisi-
tion varied for the 10 remaining case patients who were not
known to be noncompliant (one from West Africa, one from
East Africa, one from Central Africa,† five from Central
America, and two from Papua New Guinea). Blood samples
were not available; therefore, serum drug levels were not mea-
sured for any of these patients. The probable explanations for
these cases are either inappropriate dosing or noncompliance
that was not reported. Evidence is lacking that would indi-
cate any new area of chloroquine-resistant P. vivax.
Cases of P. falciparum and P. malariae After Recom-
mended Prophylaxis Use. The remaining 105 cases of
malaria reported among persons who had taken a recom-
mended antimalarial drug for chemoprophylaxis include 61
cases of P. falciparum, 16 cases of P. malariae, one case of mixed
infection, and 27 cases in which the infecting species was
unidentified.
† East, West, and Central Africa: Angola, Benin, Burkina Faso, Burundi,
Cameroon, Cape Verde Islands, Central African Republic, Chad, Comoros,
Congo, Côte d’Ivoire, Democratic Republic of the Congo, Djibouti,
Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea,
Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania,
Mauritius, Mozambique, Niger, Nigeria, Réunion, Rwanda, São Tomé
and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Togo,
Uganda, Tanzania, Zambia, and Zimbabwe.
TABLE 5. Number of imported malaria cases among U.S. and foreign civilians, by region of acquisition — United States, 2000*
United States Foreign Total
Area or region No. (%) No. (%) No. (%)
Africa 555 (67.3) 150 (42.4) 705 (59.8)
Asia 106 (12.8) 90 (25.4) 196 (16.6)
Central America/the Caribbean 90 (10.9) 81 (22.9) 171 (14.5)
South America 37 (4.5) 14 (4.0) 51 (4.3)
North America 11 (1.3) 15 (4.2) 26 (2.2)
Oceania 21 (2.5) 0 (0) 21 (1.8)
Europe/Newly Independent States 0 (0) 0 (0) 0 (0)
Unknown† 5 (0.6) 4 (1.1) 9 (0.8)
Total 825 (100.0) 354 (100.0) 1,179 (100.0)
* Persons for whom U.S. or foreign status is not known are excluded.† Region of acquisition is unknown.
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A total of 59 of the 61 P. falciparum cases among those who
reported taking a recommended antimalarial drug were
acquired in Africa, one in the Caribbean, and one in South
America. In 24 (39.3%) of these 61 cases, noncompliance
with antimalarials was reported. Of the remaining 37 cases of
P. falciparum for which patient compliance was unknown,
the majority were acquired in Africa (n = 35): 24 in West
Africa, seven in East Africa, one in Central Africa, one in
Southern Africa,§ and two in an unspecified African region.
Two cases were acquired outside Africa: one in the Caribbean
(Haiti) and one in South America (Brazil). Serum drug levels
were not available for any of these 37 patients.
Eight of the 16 P. malariae cases among those who reported
taking a recommended antimalarial drug were acquired in
Africa. In three (18.8%) of these 16 cases, noncompliance
with antimalarials was reported. In the 13 remaining cases,
whether the patient complied with prophylaxis was unknown;
four had traveled in the Americas, five in Africa, three in Asia,
and one in Oceania.
Purpose of Travel
Purpose of travel to malaria-endemic areas was reported for
635 (77.0%) of the 825 U.S. civilians with imported malaria
(Table 6). Of the U.S. civilians with malaria, the largest per-
centage (35.9%) were persons who had visited friends or rela-
tives in malarious areas; the second and third largest
percentages, 10.3% and 10.2%, had traveled for tourism and
to do missionary work, respectively.
Malaria During Pregnancy
A total of 35 cases of malaria were reported among preg-
nant women in 2000, representing 7.8% of cases among
women. Fifteen (42.9%) were among U.S. civilians. Eleven
of these 15 women (73.3%) had traveled to visit friends and
relatives, of whom 72.7% traveled in Africa. Only 1 pregnant
woman (6.9%) reported taking prophylaxis, compared with
31.1% of nonpregnant women. Twelve women (86.7%) were
hospitalized, compared with 56.3% of nonpregnant women.
Malaria Acquired in the United States
Congenital Malaria
Two cases of congenital malaria were reported in 2000 and
are described in the following case reports:
• Case 1. On September 7, 2000, a previously healthy
10-week-old female infant residing in North Carolina
experienced fever and dark urine (10). Examination
revealed a temperature of 103.7ºF but no other abnor-
mal findings. Laboratory studies included an elevated
white blood cell count (24,600/µL) and low hemoglobin
(8.7 g/dL). She was admitted to a local hospital to rule
out sepsis, and intravenous therapy with ampicillin and
cefotaxime was begun. On September 8, blood films for
malaria were obtained and were reported the next day to
contain P. malariae. Treatment with chloroquine was ini-
tiated. Bacterial cultures of urine, blood, and cerebrospi-
nal fluid obtained at admission indicated no growth. The
child’s clinical status improved, and she was discharged
on September 13, having completed chloroquine treat-
ment in the hospital.
The mother reported that her pregnancy had been
uncomplicated, and the neonate had been born by cesar-
ean delivery because of failure to progress during labor.
The infant had not traveled outside her home city or
received any blood products. Both parents had emigrated
from the Democratic Republic of the Congo (formerly
Zaire), the father 5 years previously and the mother
4 years previously. The mother reported being treated for
malaria with a full course of chloroquine before leaving
the Congo in 1996. Both parents reported no episodes of
malaria, febrile illness, foreign travel, or blood transfu-
sion after arriving in the United States.
Pretreatment malaria testing of the mother with thick and
thin blood films prepared at four different times did not
indicate malaria parasites (drawn September 10, 12, 13,
and 21). Subsequent serologic testing revealed positive
immunoglobulin G (IgG) titers against P. falciparum and
P. malariae (both 1:16,384), and against P. vivax and
P. ovale (both 1:1,024), indicating previous infection with
malaria. Polymerase chain reaction (PCR) analysis on
blood collected on September 22 was negative for
Plasmodium species. However, she was presumptively
treated with chloroquine.
TABLE 6. Number of imported malaria cases among U.S.
civilians, by purpose of travel at the time of acquisition —
United States, 2000
Imported Cases
Category No. (%)
Visiting friends/relatives 296 (35.9)
Tourism 85 (10.3)
Missionary or dependent 84 (10.2)
Business representative 60 (7.3)
Student/teacher 48 (5.8)
Peace Corps volunteer 21 (2.6)
Refugee/immigrant 1 (0.1)
Air crew/sailor 3 (0.4)
Other/mixed purpose 37 (4.5)
Unknown 190 (23.0)
Total 825 (100.0)
§ Southern Africa: Botswana, Lesotho, Namibia, Saint Helena, South Africa,
and Swaziland.
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• Case 2. In November 2000, a male infant, aged 1 month,
was admitted to a Georgia hospital because of poor oral
intake and pallor. On examination, the baby was irritable
and pale, with a heart rate of 95 beats/minute and mild
hepatosplenomegaly. Laboratory examination revealed a
hemoglobin of 2.5 g/dL, and a malaria blood film indi-
cated P. vivax. The infant was treated with oral chloro-
quine and recovered without complications.
The infant was born by normal spontaneous vaginal
delivery to a Guatemalan mother, who reported a history
of malaria in Guatemala in November 1999, for which
she was treated with proguanil. She immigrated to the
United States in March 2000, where she continued to do
well until April. At that time, she reportedly experienced
fever and chills and self-medicated with an unknown oral
medication. The mother’s thick and thin blood smears
were negative, as was PCR. Immunofluorescent assay
titers performed on the mother’s serology were 1:256 to
P. vivax, 1:64 to P. falciparum, 1:64 to P. malariae, and
1:64 to P. ovale, indicating prior infection with malaria.
Induced Malaria
Two cases of induced malaria were reported in 2000 and
are described in the following case reports:
• Case 1. On August 4, 2000, a female nurse aged 55 years,
sustained a needle-stick injury while caring for a patient
in a Massachusetts hospital emergency department. The
patient had returned recently from Cote d’Ivoire and had
a fever. Infection with P. falciparum was diagnosed, and
the patient responded well to treatment with quinine and
doxycycline.
On September 11, the nurse experienced fever, chills, and
vomiting. Infection with P. falciparum was diagnosed, and
the nurse was admitted to the hospital and treated suc-
cessfully with quinine and doxycycline. She reported no
travel to malaria-endemic areas nor transfusion of blood
products.
• Case 2. On September 23, 2000, a man aged 71 years
who had a history of hypertension, hypercholesterolemia,
diabetes mellitus, and endocarditis was admitted to a
Massachusetts hospital because of progressive weakness,
nausea, and vomiting. Acalculous cholecystitis was diag-
nosed. Review of the complete blood count was suspi-
cious for Babesia. The patient was administered a single
dose of intravenous doxycycline and started on intrave-
nous clindamycin at a dosage of 600 mg every 8 hours.
Blood films sent to CDC revealed P. falciparum. Therapy
was changed to quinine and doxycycline and the patient
improved.
The patient reported no recent travel, having been house-
bound for the previous 4–5 months because of his chronic
illnesses. He had received 1 unit of packed red blood cells
(PRBC) on July 7 and 13; he had also received 1 unit of
PRBC, 6 units of platelets, and 6 units of fresh frozen
plasma during coronary artery bypass graft and mitral
valve repair on August 8, and 1 unit of PRBC for
gastrointestinal bleeding on September 8. Five of the six
platelet donors and all four PRBC donors were traced,
and their blood films, PCR, and serology did not indi-
cate malaria. One donor refused to cooperate with the
trace-back investigation.
Investigation revealed that a nurse, who had cared for
this patient during his emergency room visit on Septem-
ber 8, had previously experienced P. falciparum malaria
(see case 1 in this section). The nurse’s exposure was
thought to be from a needle-stick injury sustained at
another local hospital on August 4. At that time, she had
been caring for a patient who was diagnosed with
P. falciparum after a trip to Cote d’Ivoire.
PCR analysis demonstrated that the parasite identified
in induced cases 1 and 2 are clonal (i.e., related). These
results strongly imply that malaria was transmitted
between the two persons. Technical difficulties with
specimens from the Cote d’Ivoire patient prohibited PCR
analysis to determine clonal identity.
Deaths Attributed to Malaria
Six deaths attributable to malaria were reported during 2000
and are described in the following case reports:
• Case 1. On January 16, 2000, a female aged 91 years
who was a resident of a long-term care facility in Califor-
nia was evaluated by her physician and determined to
have microcytic anemia (hemoglobin 8.3 g/dL), throm-
bocytopenia (platelet count: 53,000/µL), and renal
insufficiency (blood urea nitrogen: 39 mg/dL and creati-
nine: 1.4 mg/dL). A blood film indicated P. malariae,
and she was treated with chloroquine. Years had passed
since she had traveled to a malarious area (China). Her
course was complicated by pneumonia, and she died on
January 26.
• Case 2. On May 5, 2000, a female aged 47 years and a
resident of Kenya arrived in California to visit family.
She visited a physician on May 16 with complaints of
nausea and abdominal pain; a urinary tract infection was
diagnosed, and she was treated with nitrofurantoin. She
was examined at a California hospital the following day;
she was jaundiced, and hepatitis was diagnosed. She
refused hospitalization and insisted on continuing her
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travels to Canada on May 18. She required a wheelchair
for transport in the airport but was able to walk onto the
airplane. While on the airplane she felt ill, vomited, and
collapsed in the airplane’s bathroom. The airplane was
diverted to an airport in Nevada, and she was transported
to an emergency department where she was found to be
comatose and in acute respiratory failure. Her laboratory
examinations revealed P. falciparum malaria (9.3% para-
sitemia) as well as metabolic acidosis, thrombocytopenia
(platelet count: 13,000/µL), and abnormal liver function
(aspartate aminotransferase: 117 U/L; alanine aminotrans-
ferase: 71U/L; total bilirubin: 8.2 mg/dL). Computer-
ized tomography of the head indicated probable cerebral
edema. Therapy with intravenous quinidine gluconate was
begun. Her condition deteriorated, necessitating assisted
ventilation. Her course was further complicated by
supraventricular tachycardia and later bradycardia and
hypotension unresponsive to therapy with intravenous
fluids and vasopressors, and she died in the emergency
department. Blood cultures, taken on arrival at the hos-
pital, later grew both Staphylococcus aureus  and
coagulase-negative staphylococcus.
• Case 3. On November 7, 2000, a woman aged 24 years
was examined in the emergency department of a Vermont
hospital and was prescribed antibiotics. She was not
admitted to the hospital and was found deceased 4 days
later. She had recently been on a 3-month trip to Ghana,
and she had begun experiencing symptoms within days
after returning to the United States. She did not take pro-
phylaxis during her travel in Africa. Her blood films
revealed P. falciparum, and the state medical examiner
reported the cause of death as cerebral malaria secondary
to P. falciparum.
• Case 4. On September 22, 2000, a Senegalese man aged
39 years who reported a history of congestive heart fail-
ure (CHF), peptic ulcer disease, and hepatitis, was treated
at a Georgia hospital. The patient had arrived in the
United States approximately 2 months earlier to visit
friends. On examination, he was diaphoretic, but with-
out fever, and in moderate respiratory distress; he also
had signs and symptoms consistent with CHF. The
patient was admitted with a diagnosis of CHF and was
treated with intravenous diuretics and inotropic agents.
After admission, he became nauseated and febrile. Labo-
ratory studies demonstrated abnormal liver function,
although viral hepatitis serology tests were negative.
Plasmodium parasites were identified on a malaria blood
film (September 24), and treatment with quinine and
doxycycline was begun. The species was subsequently
identified as nonfalciparum malaria, and the treatment
was changed to chloroquine. On September 26, the
patient was lethargic with altered mental status, and he
was transferred to the medical intensive care unit. On
September 27, the patient suffered a cardiac arrest and
was unable to be resuscitated. Species confirmation of
blood films, taken during his admission, occurred post-
mortem and revealed P. ovale.
• Case 5. On April 3, 2000, a man aged 55 years with
multiple medical problems was examined at an emergency
department of a Florida hospital. He complained of gen-
eralized weakness, cough, and fever, and on examination,
he was hypotensive and febrile (105ºF). Malaria was
diagnosed (species undetermined), and the patient was
admitted to the intensive care unit. He was initially treated
with oral chloroquine and then oral quinine sulfate.
His medical history included atrial fibrillation, sleep
apnea, liver disease, and morbid obesity. The patient had
been noncompliant with his regular medications before
hospitalization. Moreover, the patient, a U.S. civilian, had
recently traveled to Mexico, Nicaragua, Honduras, and
Ecuador, and he had not taken any prophylaxis during
this 6-week trip. He returned to the United States on
March 30, a total of 4 days before admission to the hos-
pital. His course was complicated by pulmonary embo-
lism, cardiac arrhythmia (supraventricular tachycardia and
atrial fibrillation), congestive cardiac failure, disseminated
intravascular coagulation, renal failure, retroperitoneal
bleeding, and malignant hyperthermia. He received mul-
tiple transfusions of blood products. On April 20, as he
was being prepared for insertion of an inferior vena cava
filter, he suffered a cardiac arrest and died. Species con-
firmation of blood films taken during his admission
occurred postmortem and demonstrated P. falciparum.
• Case 6. On December 17, 2000, a male sailor from West
Africa, aged 37 years, was admitted to a Florida hospital
after a fall onboard his ship. He complained of general-
ized weakness, cough, and loss of appetite during the pre-
vious weeks. He had recently traveled from Liberia
through Ghana and the Cape Verde Islands and arrived
in Baltimore, Maryland, on December 12. While in Bal-
timore, he was seen by a physician and was prescribed
erythromycin for his symptoms. He had not been taking
any prophylaxis for malaria.
On examination, he was febrile (101.6ºF), tachycardic
(138 beats/minute) and jaundiced. His laboratory test
results revealed a normal white blood cell count
(8,100/µL), thrombocytopenia (platelets: 68,000/µL), and
anemia (hemoglobin: 12.2 g/dL). He was admitted with
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a diagnosis of malaria (P. falciparum) and acute renal fail-
ure, and treated with quinine and doxycycline. His hos-
pital course was further complicated by respiratory failure
and gastrointestinal (GI) bleeding. He was placed on
assisted ventilation, and he received multiple blood trans-
fusions for anemia secondary to malaria and GI bleed-
ing. Subsequent malaria blood films, on December 20
and 21, did not indicate malaria parasites. However, the
patient’s condition continued to deteriorate and he
experienced multiorgan failure. Despite supportive
therapy, the patient died on January 5, 2001.
Discussion
A total of 1,402 cases of malaria were reported to CDC for
2000, representing a 9.0% decrease from the 1,540 cases
reported for 1999. This change primarily resulted from a
decrease in cases acquired in Africa and the Americas. Begin-
ning in 2000, CDC routinely contacts state health depart-
ments to ask for outstanding reports from the previous
reporting year or for a statement that reporting is complete.
The decrease in cases in 2000, compared with 1999, possibly
is a result of expected variation in the reporting system,
although other possibilities include decreased international
travel, changing patterns of travel (e.g., immigration from
malarious areas or adventure tourism), or an increased use of
effective antimalarial chemoprophylaxis.
One reason for conducting malaria surveillance is to moni-
tor for prophylaxis failures that might indicate emergence of
drug resistance; however, >70% of imported malaria among
U.S. civilians occurred among persons who were either not
taking prophylaxis or were taking nonrecommended prophy-
laxis for the region to which they were traveling. Among the
117 cases where appropriate prophylaxis was reported, 60 (i.e.,
37 P. falciparum, 10 P. vivax, and 13 P. malariae) had insuffi-
cient information to determine whether these represented
problems with adherence while using correct antimalarial
chemoprophylaxis or emerging drug resistance. No conclu-
sive evidence existed to indicate a single national or regional
source of infection among this group of patients or the fail-
ure of a particular chemoprophylactic regimen. Health-care
providers are encouraged to contact CDC rapidly whenever
they suspect chemoprophylaxis failure, thus enabling measure-
ment of serum drug levels of the antimalarial drugs in question.
In 2001, to be better able to evaluate chemoprophylaxis
failures, CDC revised the NMSS case report form to facili-
tate collection of more thorough data regarding chemopro-
phylaxis. The current form solicits more detailed information
regarding the prescribed regimen, the degree of compliance
with the regimen, and the reasons for noncompliance, if any.
Data gathered from the responses will be useful in generating
public health messages to improve use of antimalarial chemo-
prophylaxis, and therefore decrease malaria-associated mor-
bidity and mortality among U.S. civilians.
The importance of taking correct precautions and chemo-
prophylaxis is underscored by the six fatal cases of malaria
that occurred in the United States in 2000. An earlier review
of deaths attributed to malaria in the United States identified
certain risk factors for fatal malaria, including failure to take
recommended antimalarial chemoprophylaxis, refusal of or
delay in seeking medical care, and misdiagnosis (11).
The occurrence of 15 cases of malaria among pregnant U.S.
civilians is cause for concern also. Malaria during pregnancy
among nonimmune women is more likely to result in severe
disease or contribute to an adverse outcome for the woman
than malaria in a nonpregnant woman (12); the fetus might
be adversely affected as well (13). Pregnant travelers should
be counseled to avoid travel to malarious areas, if possible. If
deferral of travel is impossible, pregnant women should be
informed that the risks for malaria outweigh those associated
with prophylaxis and that safe chemoprophylaxis regimens
are available. Specific guidance for pregnant travelers is avail-
able from CDC’s website at http://www.cdc.gov/travel/
mal_preg_pub.htm.
Signs and symptoms of malaria are often nonspecific, but
fever is usually present. Other symptoms include headache,
chills, increased sweating, back pain, myalgia, diarrhea, nau-
sea, vomiting, and cough. Prompt diagnosis requires that
malaria be included in the differential diagnosis of illness in a
febrile person with a history of travel to a malarious area.
Clinicians should ask all febrile patients for a travel history,
including when evaluating febrile illnesses among international
visitors, immigrants, refugees, migrant laborers, and interna-
tional travelers.
Treatment for malaria should be initiated immediately
after the diagnosis has been confirmed by a positive blood
film. Treatment should be determined on the basis of the
infecting Plasmodium species, the probable geographic origin
of the parasite, the parasite density, and the patient’s clinical
status (14). Although nonfalciparum malaria rarely causes
complications, persons with P. falciparum infection are at risk
for developing life-threatening complications.
Health-care workers should be familiar with prevention,
recognition, and treatment of malaria and are encouraged to
consult appropriate sources (Table 7) for malaria treatment
recommendations or call CDC’s National Center for Infec-
tious Diseases, Division of Parasitic Diseases at 770-488-7788.
Detailed recommendations for preventing malaria are
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available 24 hours/day from CDC by telephone at 877-394-
8747 (toll-free voice information system) or 888-232-3299
(toll-free facsimile request line), or on the Internet at http://
www.cdc.gov/travel/diseases.htm#malaria. In addition, CDC
biannually publishes recommendations in the Health Infor-
mation for International Travel (9), which is available for
purchase from the Public Health Foundation at 877-252-1200
or 301-645-7773; it is also available and updated more fre-
quently on CDC’s Internet site at http://www.cdc.gov/travel.
CDC provides support for the diagnosis of malaria through
DPDx, a program that enhances diagnosis of parasitic dis-
eases throughout the world. It includes an Internet site,
http://www.dpd.cdc.gov/dpdx, that contains information
regarding laboratory diagnosis, geographic distribution, clini-
cal features, treatment, and life cycles of >100 parasite spe-
cies. The DPDx Internet site is also a portal for diagnostic
assistance for health-care providers through telediagnosis.
Digital images captured from diagnostic specimens are sub-
mitted for diagnostic consultation through electronic mail.
Because laboratories can transmit images to CDC and rap-
idly obtain answers to their inquiries, this system allows more
efficient diagnosis of difficult cases and more rapid dissemi-
nation of information. Approximately 36 laboratories in 34
states have or are in the process of acquiring the hardware to
perform telediagnosis.
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TABLE 7. Sources for malaria prophylaxis, diagnosis, and treatment recommendations
Telephone number,
Type Internet address, or
of information Source Availability electronic mail address
Prophylaxis CDC’s voice information system 24 hours/day 877-394-8747
Prophylaxis CDC’s malaria facsimile 24 hours/day 888-232-3299
Prophylaxis CDC’s traveler’s health Internet site 24 hours/day http://www.cdc.gov/travel
Prophylaxis Health Information Order from
for International Travel Public Health Foundation 877-252-1200 or
 Publication Sales 301-645-7773 or
P.O. Box 753 http://www.phf.org
Waldorf, MD 20604
Prophylaxis Health Information 24 hours/day http://www.cdc.gov/travel
for International Travel
Diagnosis CDC’s Division of Parasitic Diseases 24 hours/day http://www.dpd.cdc.gov/dpdx
Diagnostic Internet site (DPDx)
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FIGURE A-1. Blood collection for thin or thick blood films
1
2
3
Select the finger
to puncture
(usually the third
or fourth finger).
Puncture the side of
the ball of the finger.
Do not make the
puncture too close to
the nail bed.
If the blood does not
well up from the puncture,
gently squeeze the finger.
To control the size of
the blood drop on the
slide, touch the finger to
4
5
Always grasp the
slide by the edges.
the slide from below.
To establish the diagnosis of malaria, a blood film must be
prepared from fresh blood obtained by pricking the patient’s
finger (Figures A-1 and A-2).* The thin film is fixed in metha-
nol before staining; the thick film is stained unfixed. Certain
hospitals have a Wright-Giemsa stain available, which is ac-
ceptable; however, Wright stain alone will not reliably indi-
cate Plasmodium parasites. For best results, the film should be
stained with a 3% Giemsa solution (pH of 7.2) for 30–45
minutes. In P. falciparum infections, the parasite density should
be estimated by counting the percentage of red blood cells
infected — not the number of parasites — under an oil
immersion lens on a thin film.
Thick blood films are more sensitive in detecting malaria
parasites because the blood is concentrated, allowing a greater
volume of blood to be examined. However, thick films are
more difficult to read, and thin films might be preferred by
laboratories that have limited experience. Plasmodium parasites
Appendix
Microscopic Procedures for Diagnosing Malaria
* In Figures A-1 and A-2, the hands are illustrated ungloved to better indicate
their placement during the procedures. However, wearing gloves while
processing blood specimens is recommended to prevent transmission of
bloodborne pathogens (MMWR 1988;37:377–82, 387–8 and MMWR
1987;36[No. S2]).
are always intracellular, and they demonstrate, if stained cor-
rectly, blue cytoplasm with a red chromatin dot. Common
errors in reading malaria films are caused by platelets overly-
ing a red blood cell, concern regarding missing a positive slide,
and misreading artifacts as parasites. Persons suspected of hav-
ing malaria, but whose blood films do not indicate the pres-
ence of parasites, should have blood films repeated
approximately every 12–24 hours for 3 consecutive days. If
films remain negative, then the diagnosis of malaria is
unlikely.
For rapid diagnosis, the thick and thin films should be made
on separate slides. The thin film should be air-dried, fixed
with methyl alcohol, and immediately stained. If no parasites
are visible on the thin film, the laboratorian should wait until
the thick film is dry, then examine it for organisms that might
not have been detected on the thin preparation.
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FIGURE A-2. Preparation of a thin and a thick blood film on the same slide
1
2
3
Touch the blood drop
with a clean slide.
Using the corner of
another slide, spread
the blood drop into the
shape of a circle
or square of ~1cm2.
Gently squeeze the
patient’s finger again,
and touch the edge of a
clean slide to the newly
formed blood drop.
4
5
6
Take this slide and hold the
edge that has the blood
drop at an ~45o angle
against the surface of the
first slide. Wait until the
blood completely
spreads along the edge of
the second slide.
While holding the second
slide at the same angle,
rapidly and smoothly push
the slide forward.
Write the identification
number on the slide.
Wait until the thick film
is completely dry
before staining it.
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